MB2 Dental Provides A New Business Model For Dental Practices

MB2 Dental offers a unique alternative to stuffy private dental practices and large impersonal corporate groups with an entrepreneurial approach. They assist providers, dental graduates and support team members with business solutions, peer to peer support, and doctor mentors. MB2 Dental understands that practices are a direct reflection of their staff. This shows in the stellar reviews by current and past employees of MB2 Dental affiliates. A great team atmosphere, unique work environment, plenty of opportunities for career growth, caring leadership and new technology were at the top of the list.

The founder and CEO, Dr. Steven Villanueva, DMD, has seen first hand the issues plaguing the dental community. He referred to what he experienced when he started out as the “trenches”. Knowing he had to challenge the traditional norms of the dental practice, Dr. Villanueva started MB2 as a dental practice development company in 2009. Siting that the less time a dentist has to worry about the business aspect of a practice, the more time they have to spend with the patient. This enhances the dental practice experience for the doctors, staff, and patients.

MB2 Dental is owned by dentists that know what other dentists need to succeed. They provide support services to its affiliates such as:

  • Human Recources
  • Credentialing
  • Compliance
  • IT
  • Billing and Collection
  • Marketing
  • Recruiting
  • Procurement
  • Business Development and Training

Affiliate locations in Texas, New Mexico, Oklahoma, Louisiana, Tennessee, and Alaska.

In the dental practice not unlike other medical practices, there has to be continuity, accountability, and stability. Balancing these attributes with the individuality and uniqueness of its staff is tricky. If not properly managed, one aspect is sure to suffer as the other flourishes. Ensuring all aspects of the dental affiliate works harmoniously is where MB2 Dental comes in.

His youtube channel


Professor and Chief Editor- Mikhail Blagosklonny

Cancer has been a worldwide crisis, and scientist and world researchers have been conducting studies for cancer therapy as well as courses. Medical researchers have been conducting various studies which some of them have been of great help to the cancer patients.

Mikhail Blagosklonny is a medical professor who has a great passion for cancer patients. He can well be described as an expert in oncology and aging. After his High School graduation, Dr. Mikhail attended Pavlov State Medical University, St Petersburg. Professor Mikhail Blagosklonny graduated with a masters degree in internal medicine and Ph.D. in experimental medicine from the same University.

Dr. Mikhail is very passionate about medicine and has been making continuous efforts to improve the medical sector. Later Blagosklonny joined New York Medical College where he served as an associate professor of medicine on impactjourals.com. Mikhail has served in various medical institutions holding top positions including; Ordway Research Institute as a Senior Scientist where he worked for seven years.

View Mikhail’s profile on Google Scholar

In 2009 scientist Mikhail Blagosklonny was appointed to serve as a professor of oncology at Roswell Park Cancer Institute. Mikhail is responsible for teaching as well as conducting research in various field that concern oncology. Professor Mikhail is also an author who has written more than 270 books, and the books have received 30000 citations, and have given him an index of 83. Mikhail has been carrying researchers that have revolving around; molecular biology, tumor suppressor, oncogenes, and tumor transduction. Mikhail has lately been conducting unique and new strategies that have developed over the years making him one of the top researchers on cancer and developing therapeutics.

Mikhail Blagosklonny has led various researchers, but one of his famous papers is the function of TOR signaling in aging. In his studies, he mentions that the over development of cells is the primary cause of cancer is aging and that cancer is a sign of aging. Scientists Blagosklonny advice the use of rapamycin on tandfonline.com as an anti-aging drug. One of his articles has well demonstrated how the anti-aging drug will assist in slowing down cellular senescence which is impairment with age. Mikhail is a chief editor in aging and also a founding editor. He is a chief editor at Oncotarget a medical journal which writes on oncology.

Follow Mikhail on Loop